دورية أكاديمية

Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study

التفاصيل البيبلوغرافية
العنوان: Efficacy, safety, and immunogenicity of the human papillomavirus 16/18 AS04-adjuvanted vaccine in women older than 25 years: 4-year interim follow-up of the phase 3, double-blind, randomised controlled VIVIANE study
المؤلفون: Skinner, S Rachel, Szarewski, Anne, Romanowski, Barbara, Garland, Suzanne M, Lazcano-Ponce, Eduardo, Salmerón, Jorge, Del Rosario-Raymundo, M Rowena, Verheijen, René H M, Quek, Swee Chong, da Silva, Daniel P, Kitchener, Henry, Fong, Kah Leng, Bouchard, Céline, Money, Deborah M, Ilancheran, Arunachalam, Cruickshank, Margaret E, Levin, Myron J, Chatterjee, Archana, Stapleton, Jack T, Martens, Mark, Quint, Wim, David, Marie-Pierre, Meric, Dorothée, Hardt, Karin, Descamps, Dominique, Geeraerts, Brecht, Struyf, Frank, Dubin, Gary
المصدر: In The Lancet 20 December 2014-2 January 2015 384(9961):2213-2227
قاعدة البيانات: ScienceDirect
الوصف
تدمد:01406736
DOI:10.1016/S0140-6736(14)60920-X